NCT05819853View on ClinicalTrials.gov

Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 3, 2023

Primary Completion Date

February 1, 2028

Study Completion Date

June 30, 2028

Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral OvariesObese
Interventions
DRUG

Semaglutide Injectable Product (Wegovy and/or Ozempic)

10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg

Trial Locations (1)

80045

RECRUITING

University of Colorado Anschutz/Children's Hospital Colorado Aurora, Aurora

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Colorado, Denver

OTHER